Kazia Therapeutics: Edison Open House Healthcare 2022

Kazia Therapeutics: Edison Open House Healthcare 2022

Kazia Therapeutics — 9 videos in collection

More on this equity

Kazia Therapeutics’ lead asset is paxalisib, a PI3K inhibitor licensed from Genentech that can cross the BBB. It is entering a pivotal study for GBM and is being investigated for other brain cancers such as breast cancer brain metastases.
• Tell us about Kazia’s unique business model.
• What indications are you focusing on?
• What is the current status of paxalisib and what is the plan for the year ahead?
• How large do you anticipate the unmet need in the glioblastoma market to be?
• Is paxalisib being considered for any other brain cancers?
• What is the current status of EVT801 and what is the plan for the year ahead?
• Do the tumours you’re targeting have a genetic signature? What is the mechanism here?
• Which milestones should investors focus on in the coming year?


You may also be interested in these:

Subscribe to Edison

Get access to the very latest content matched to your personal investment style.

Sign up for free